These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33599307)

  • 1. Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Leon P; Cancel-Tassin G; Bourdon V; Buecher B; Oudard S; Brureau L; Jouffe L; Blanchet P; Stoppa-Lyonnet D; Coulet F; Sobol H; Cussenot O
    Prostate; 2021 May; 81(6):318-325. PubMed ID: 33599307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
    Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
    Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada.
    Wolpert N; Warner E; Seminsky MF; Futreal A; Narod SA
    Clin Breast Cancer; 2000 Apr; 1(1):57-63; discussion 64-5. PubMed ID: 11899391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
    Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
    Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA2 gene mutations in Slovenian male breast cancer patients.
    Besic N; Cernivc B; de Grève J; Lokar K; Krajc M; Novakovic S; Zgajnar J; Teugels E
    Genet Test; 2008 Jun; 12(2):203-9. PubMed ID: 18439106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
    Kote-Jarai Z; Leongamornlert D; Saunders E; Tymrakiewicz M; Castro E; Mahmud N; Guy M; Edwards S; O'Brien L; Sawyer E; Hall A; Wilkinson R; Dadaev T; Goh C; Easton D; ; Goldgar D; Eeles R
    Br J Cancer; 2011 Oct; 105(8):1230-4. PubMed ID: 21952622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
    BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.
    Bonaïti B; Alarcon F; Andrieu N; Bonadona V; Dondon MG; Pennec S; Stoppa-Lyonnet D; Bonaïti-Pellié C; Perdry H
    J Med Genet; 2014 Feb; 51(2):114-21. PubMed ID: 24343917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
    Edwards SM; Evans DG; Hope Q; Norman AR; Barbachano Y; Bullock S; Kote-Jarai Z; Meitz J; Falconer A; Osin P; Fisher C; Guy M; Jhavar SG; Hall AL; O'Brien LT; Gehr-Swain BN; Wilkinson RA; Forrest MS; Dearnaley DP; Ardern-Jones AT; Page EC; Easton DF; Eeles RA;
    Br J Cancer; 2010 Sep; 103(6):918-24. PubMed ID: 20736950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.
    Edwards SM; Kote-Jarai Z; Meitz J; Hamoudi R; Hope Q; Osin P; Jackson R; Southgate C; Singh R; Falconer A; Dearnaley DP; Ardern-Jones A; Murkin A; Dowe A; Kelly J; Williams S; Oram R; Stevens M; Teare DM; Ponder BA; Gayther SA; Easton DF; Eeles RA; ;
    Am J Hum Genet; 2003 Jan; 72(1):1-12. PubMed ID: 12474142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
    Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
    Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.